000			01446 a2200349 4500
005			20250511180022.0
264		0	_c19920611
008			199206s 0 0 eng d
022			_a0197-2456
024	7		_a10.1016/0197-2456(92)90030-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aLachin, J M
245	0	0	_aTermination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. _h[electronic resource]
260			_bControlled clinical trials _cFeb 1992
300			_a62-79 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aData Interpretation, Statistical
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aKidney Failure, Chronic _xmortality
650	0	4	_aLupus Nephritis _xmortality
650	0	4	_aMulticenter Studies as Topic _xstatistics & numerical data
650	0	4	_aPlasmapheresis
650	0	4	_aPrednisone _xtherapeutic use
650	0	4	_aProportional Hazards Models
650	0	4	_aRandomized Controlled Trials as Topic _xstatistics & numerical data
700	1		_aLan, S P
773	0		_tControlled clinical trials _gvol. 13 _gno. 1 _gp. 62-79
856	4	0	_uhttps://doi.org/10.1016/0197-2456(92)90030-4 _zAvailable from publisher's website
999			_c1322188 _d1322188